Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Dec;101(12):e485-e487.
doi: 10.3324/haematol.2016.151266. Epub 2016 Aug 18.

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial

Maximilian Merz  1 , Hans Salwender  2 , Mathias Haenel  3 , Elias K Mai  4 , Uta Bertsch  4   5 , Christina Kunz  6 , Thomas Hielscher  6 , Igor W Blau  7 , Christof Scheid  8 , Dirk Hose  4 , Anja Seckinger  4 , Anna Jauch  9 , Jens Hillengass  4 , Marc S Raab  4 , Baerbel Schurich  4 , Markus Munder  10 , Peter Brossart  11 , Christian Gerecke  12 , Hans-Walter Lindemann  13 , Matthias Zeis  14 , Katja Weisel  15 , Jan Duerig  16 , Hartmut Goldschmidt  4   5
Affiliations
Clinical Trial

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial

Maximilian Merz et al. Haematologica. 2016 Dec.
No abstract available

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Richardson PG, Delforge M, Beksac M, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2012;26(4):595–608. - PubMed
    1. Dimopoulos MA, Mateos M-V, Richardson PG, et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol. 2011;86(1):23–31. - PubMed
    1. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431–440. - PubMed
    1. Arnulf B, Pylypenko H, Grosicki S, et al. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica. 2012;97(12):1925–1928. - PMC - PubMed
    1. Merz M, Salwender H, Haenel M, et al. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. Haematologica. 2015;100(7):964–969. - PMC - PubMed

Publication types

MeSH terms